A novel c-Met targeting antibody drug conjugate for NSCLC

被引：1
|
作者：
Li, Lingna
Fells, Cathrine
Guo, Julia
Muyot, Pia
Gros, Edwige
Zhang, Yanliang
Sun, Yingqing
Zhang, Hong
Fu, Yanwen
Zhu, Tong
Cao, Jian
Kaufmann, Gunnar
Chen, Gang
Miao, Zhenwei
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3897
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET
    Wu, Yi
    Yu, Min
    Sun, Zujun
    Hou, Weihua
    Wang, Yuxiong
    Yuan, Qingyun
    Mo, Wei
    PROTEIN AND PEPTIDE LETTERS, 2017, 24 (12): : 1105 - 1112
  • [32] Radiosensitization of brain metastasis by targeting c-MET
    Yang, Heekyoung
    Lee, Hye Won
    Kim, Yonghyun
    Lee, Yeri
    Choi, Yeon-Sook
    Kim, Kang Ho
    Jin, Juyoun
    Lee, Jeongwu
    Joo, Kyeung Min
    Nam, Do-Hyun
    LABORATORY INVESTIGATION, 2013, 93 (03) : 344 - 353
  • [33] PET imaging of c-Met activity in NSCLC using 18F Labelled c-MET inhibitor
    Han, Zhaoguo
    Zhang, Tao
    Ke, Mingxing
    Qiao, Lina
    Wu, Zhexi
    Guan, Zhengqi
    Li, Zibo
    Wu, Zhanhong
    Sun, Xilin
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [34] Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR
    Geuijen, Cecile
    di Matteo, Mario
    Gallenne, Tristan
    Cafarello, Sarah Trusso
    Nijhuis, Roy
    Visser, Therese
    Bartelink, Willem
    Bartelink-Clements, Carina
    Eppink, Berina
    Klooster, Rinse
    Dekruif, John
    Mazzone, Massimiliano
    Throsby, Mark
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [35] Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
    Huang, Lei
    Xie, Kun
    Li, Hongwen
    Wang, Ruiqin
    Xu, Xiaoqing
    Chen, Kaiming
    Gu, Hua
    Fang, Jianmin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3201 - 3214
  • [36] Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC
    Jacobs, Ryan
    Fong, Jason
    Bomgarden, Ryan
    Rogers, John
    Puri, Neelu
    CANCER RESEARCH, 2012, 72
  • [37] First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: II) in vivo activity
    Goetsch, Liliane
    Lepecquet, Anne-Marie
    Geronimi, Fabien
    Gonzalez, Alexandra
    Robert, Alain
    Chenu, Stephane
    Corbiere, Jean-Claude
    Bailly, Christian
    Corvaia, Nathalle
    CANCER RESEARCH, 2009, 69
  • [38] Isothiocyanatostilbenes as novel c-Met inhibitors
    Gray, Alana L.
    Coleman, David T.
    Castore, Reneau F.
    Mohyeldin, Mohamed M.
    El Sayed, Khalid A.
    Cardelli, James A.
    ONCOTARGET, 2015, 6 (38) : 41180 - 41193
  • [39] CLINICAL PHARM ACOKINETICS OF ABBV-400, A NOVEL C-MET-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Biesdorf, C.
    Brunsdon, P.
    Sharma, M.
    Powderly, J.
    Aristide, M. Neagu
    Freise, K.
    Menon, R.
    Parikh, A.
    Jennaro, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S63 - S63
  • [40] Isothiocyanatostilbenes as novel c-Met inhibitors
    Gray, A. L.
    Coleman, D. T.
    Castore, R. F.
    Mohyeldin, M. M.
    El Sayed, K. A.
    Cardelli, J. A.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
12345